Literature DB >> 15016493

Scale up: meeting targets in global tuberculosis control.

Gijs Elzinga1, Mario C Raviglione, Dermot Maher.   

Abstract

Despite great progress, global targets for tuberculosis case detection and cure might not be reached by 2005. In particular, there is a serious case-detection gap between estimated annual incident cases and those reported under the strategy for tuberculosis control branded as DOTS. Delays in reaching targets result in lack of effect on incidence of disease, which is of particular concern in regions where incidence is increasing-eg, sub-Saharan Africa and the former Soviet Union. Four key actions will speed up progress towards reaching global targets: 1) equipping national tuberculosis programmes to have a stewardship role in engaging all health providers in implementing the DOTS strategy; 2) establishing the feasibility of national certification systems of DOTS coverage; 3) promoting community action to contribute to patient care and to voice demand for the DOTS strategy; and 4) increasing support to sub-Saharan Africa for implementation of a strategy of expanded scope to counter HIV-1-fuelled tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016493     DOI: 10.1016/S0140-6736(04)15698-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

1.  The long-term health and economic benefits of DOTS implementation in Ecuador.

Authors:  Olivia Oxlade; Judyth Vaca; Elizabeth Romero; Kevin Schwartzman; Brian Graham; Lucero Hernandez; Terry Tannenbaum; Dick Menzies
Journal:  Can J Public Health       Date:  2006 Jan-Feb

2.  A novel indigoid anti-tuberculosis agent.

Authors:  Larry L Klein; Valentina Petukhova; Baojie Wan; Yuehong Wang; Bernard D Santasiero; David C Lankin; Guido F Pauli; Scott G Franzblau
Journal:  Bioorg Med Chem Lett       Date:  2013-11-21       Impact factor: 2.823

3.  Asymmetry and aging of mycobacterial cells lead to variable growth and antibiotic susceptibility.

Authors:  Bree B Aldridge; Marta Fernandez-Suarez; Danielle Heller; Vijay Ambravaneswaran; Daniel Irimia; Mehmet Toner; Sarah M Fortune
Journal:  Science       Date:  2011-12-15       Impact factor: 47.728

4.  Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study.

Authors:  Max R OʼDonnell; Allison Wolf; Lise Werner; C Robert Horsburgh; Nesri Padayatchi
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

Review 5.  Long term efficacy of DOTS regimens for tuberculosis: systematic review.

Authors:  Helen S Cox; Martha Morrow; Peter W Deutschmann
Journal:  BMJ       Date:  2008-02-04

6.  Determinants of mortality in elderly patients with tuberculosis: a population-based follow-up study.

Authors:  Y-F Yen; J-Y Feng; S-W Pan; P-H Chuang; V Y-F Su; W-J Su
Journal:  Epidemiol Infect       Date:  2017-02-13       Impact factor: 4.434

7.  A multi-center study to evaluate the performance of phage amplified biologically assay for detecting TB in sputum in the pulmonary TB patients.

Authors:  Changtai Zhu; Zhenling Cui; Ruijuan Zheng; Hua Yang; Ruiliang Jin; Lianhua Qin; Zhonghua Liu; Jie Wang; Zhongyi Hu
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

8.  Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.

Authors:  Chia-Lin Tseng; Olivia Oxlade; Dick Menzies; Anne Aspler; Kevin Schwartzman
Journal:  BMC Public Health       Date:  2011-01-26       Impact factor: 3.295

9.  Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti.

Authors:  Vary Jacquet; Willy Morose; Kevin Schwartzman; Olivia Oxlade; Graham Barr; Franque Grimard; Dick Menzies
Journal:  BMC Public Health       Date:  2006-08-15       Impact factor: 3.295

10.  Financing and cost-effectiveness analysis of public-private partnerships: provision of tuberculosis treatment in South Africa.

Authors:  Edina Sinanovic; Lilani Kumaranayake
Journal:  Cost Eff Resour Alloc       Date:  2006-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.